[1] Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis[J]. Lancet, 2003, 362:971-982. [2] Schneider F, Yousem SA, Oddis CV, Aggarwal R. Pulmonary pathologic manifestations of anti-alanyl-trnasynthetase (anti-PL-12)-related inflammatory myopathy[J]. Arch Pathol Lab Med, 2018, 142:191-197. [3] Miller SA, Glassberg MK, Ascherman DP. Pulmonary complications of inflammatory myopathy[J]. Rheum Dis Clin North Am, 2015, 41:249-262. [4] Jubber A, Tripathi M, Taylor J. Interstitial lung disease and inflammatory myopathy in antisynthetase syndrome with PL-12 antibody[J]. BMJ Case Rep, 2018:pii226119. [5] Van der Kooi A, Jaeger B, Pinto Y, Aronica E, de Visser M. G. P.411-two women with brachio-cervical inflammatory myopathy (BCIM) and fatal cardiomyopathy[J]. Neuromuscular Disord, 2015, 25:S308. [6] Motley SA, Sidari A, Hildebrand B, Ward IM. Cardiac manifestations of idiopathic inflammatory myopathy treated with rituximab:a single-center case series and review of the literature[J]. J Clin Rheumatol, 2019.[Epub ahead of print] [7] Kariyanna PT, Jayarangaiah A, Mahmood A, Hare M, Taklalsingh N, McFarlane IM. Rapid progression of heart failure in a patient with idiopathic inflammatory myopathy[J]. Am J Med Case Rep, 2018, 6:157-160. [8] Martínez León A, Rugeles Ni ño JP, Brandy García AM, Morís de la Tassa C, Caminal Montero L, RozadoCastaño J. Myocarditis as a form of presentation of an inflammatory autoimmune myopathy associated with anti-signal recognition particle antibodies[J]. Rev Esp Cardiol (Engl Ed), 2019, 72:422-424. [9] Selva A, Cuenca R, San José A, Navarro C, Ordi J, Bosch JA, Alijotas J, Vilardell M. Idiopathic inflammatory myopathy:analysis of 31 patients[J]. Rev Clin Esp, 1991, 189:260-263. [10] Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292:344-347. [11] Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292:403-407. [12] Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De LT, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Arthritis Rheumatol, 2017, 69:2271-2282. [13] Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA. 119th ENMC International Workshop:trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands[J]. Neuromuscul Disord, 2004, 14:337-345. [14] Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies[J]. Lancet Neurol, 2018, 17:816-828. [15] Huber AT, Lamy J, Bravetti M, Bouazizi K, Bacoyannis T, Roux C, De Cesare A, Rigolet A, Benveniste O, Allenbach Y, Kerneis M, Cluzel P, Redheuil A, Kachenoura N. Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM)[J]. Eur Radiol, 2019, 29:5139-5147. [16] Kuo GP, Carrino JA. Skeletal muscle imaging and inflammatory myopathies[J]. Curr Opin Rheumatol, 2007, 19:530-535. [17] Ran J, Ji S, Morelli JN, Wu G, Li X. T2 mapping in dermatomyositis/polymyositis and correlation with clinical parameters[J]. Clin Radiol, 2018, 73:1013-1057. [18] Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, Thornton JS, Hanna MG. MRI biomarker assessment of neuromuscular disease progression:a prospective observational cohort study[J]. Lancet Neurol, 2016, 15:65-77. [19] Klupp E, Cervantes B, Schlaeger S, Inhuber S, Kreuzpointer F, Schwirtz A, Rohrmeier A, Dieckmeyer M, Hedderich DM, Diefenbach MN, Freitag F, Rummeny EJ, Zimmer C, Kirschke JS, Karampinos DC, Baum T. Paraspinal muscle DTI metrics predict muscle strength[J]. J Magn Reson Imaging, 2019, 50:816-823. [20] Li CB, Fan GG. Reasearch status and prospect of multimodal MRI in diagnosis of idiopathic inflammatory myopathy[J]. Zhongguo Yi Xue Ying Xiang Ji Shu, 2017, 33:101-104.[李成博, 范国光. 多模态磁共振成像诊断特发性炎症性肌病的研究现状与展望[J]. 中国医学影像技术, 2017, 33:101-104.] [21] Ai T, Yu K, Gao L, Zhang P, Goerner F, Runge VM, Li X. Diffusion tensor imaging in evaluation of thigh muscles in patients with polymyositis and dermatomyositis[J]. Br J Radiol, 2014, 87:ID20140261. [22] Damon BM, Froeling M, Buck AK, Oudeman J, Ding Z, Nederveen AJ, Bush EC, Strijkers GJ. Skeletal muscle diffusion tensor-MRI fiber tracking:rationale, data acquisition and analysis methods, applications and future directions[J]. NMR Biomed, 2017, 30. [23] Subhawong TK, Wang X, Machado AJ, Mammen AL, Christopher-Stine L, Barker PB, Carrino JA, Fayad LM. 1H magnetic resonance spectroscopy findings in idiopathic inflammatory myopathies at 3T:feasibility and first results[J]. Invest Radiol, 2013, 48:509-516. [24] van Brussel M, van Oorschot JW, Schmitz JP, Nicolay K, van Royen-Kerkhof A, Takken T, Jeneson JA. Muscle metabolic responses during dynamic in-magnet exercise testing:a pilot study in children with an idiopathic inflammatory myopathy[J]. Acad Radiol, 2015, 22:1443-1448. [25] Lodi R, Taylor DJ, Tabrizi SJ, Hilton-Jones D, Squier MV, Seller A, Styles P, Schapira AH. Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy[J]. Brain, 1998, 121:2119-2126. [26] Pipitone N, Notarnicola A, Scardapane A, Spaggiari L, Levrini G, Iannone F, Lapadula G, Salvarani C. Does MRI provide an added value over serum creatine kinase measurement in myositis[J]? Ann Rheum Dis, 2015, 74:172-177. [27] Pipitone N. Value of MRI in diagnostics and evaluation of myositis[J]. Curr Opin Rheumatol, 2016, 28:625-630. [28] Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies[J]. Semin Arthritis Rheum, 2017, 46:642-649. [29] Pipitone N, Notarnicola A, Levrini G, Spaggiari L, Scardapane A, Iannone F, Lapadula G, Zuccoli G, Salvarani C. Do dermatomyositis and polymyositis affect different thigh muscle groups:a comparative MRI-based study[J]? Ann Rheum Dis, 2015, 74:603. [30] Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis[J]. Muscle Nerve, 2015, 52:956-962. [31] Zheng Y, Liu L, Wang L, Xiao J, Wang Z, Lv H, Zhang W, Yuan Y. Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle[J]. Rheumatology (Oxford), 2015, 54:1017-1024. [32] Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis[J]. Rheumatology (Oxford), 2011, 50:1153-1161. [33] Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, Paik JJ, Ahlawat S, Danoff SK, Lloyd TE, Mammen AL, Christopher-Stine L. Thigh muscle MRI in immune-mediated necrotising myopathy:extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity[J]. Ann Rheum Dis, 2017, 76:681-687. [34] Lai JM, Wu FQ, Zhou ZX, Yuan XY, Su GX, Li SN, Yan YC, Zhu J, Kang M. Role of magnetic resonance imaging in the diagnosis of juvenile dermato-myositis and polymyositis in Chinese children[J]. Zhonghua Er Ke Za Zhi, 2016, 54:767-772.[赖建铭, 吴凤岐, 周志轩, 袁新宇, 苏改秀, 李胜男, 闫淯淳, 朱佳, 康闽. 肌肉磁共振成像在儿童皮肌炎和多发性肌炎中的应用研究[J]. 中华儿科杂志, 2016, 54:767-772.] [35] Tsukita K, Yagita K, Sakamaki-Tsukita H, Suenaga T. Sporadic inclusion body myositis:magnetic resonance imaging and ultrasound characteristics[J]. QJM, 2018, 111:667-668. [36] Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis[J]. Neurology, 1997, 48:863-866. [37] Anquetil C, Boyer O, Wesner N, Benveniste O, Allenbach Y. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy[J]. Autoimmun Rev, 2019, 18:223-230. [38] Hesla RB, Karlson LK, McCauley RG. Milk of calcium fluid collection in dermatomyositis:ultrasound findings[J]. Pediatr Radiol, 1990, 20:344-346. [39] Zhu H. Two cases of juvenile dermatomyositis with calcinosis[J]. Zhongguo Hang Tian Yi Yao Za Zhi, 2002, 4:66-67.[竺红.幼年型皮肌炎并钙质沉着症2例[J]. 中国航天医药杂志, 2002, 4:66-67.] [40] Formenti P, Umbrello M, Coppola S, Froio S, Chiumello D. Clinical review:peripheral muscular ultrasound in the ICU[J]. Ann Intensive Care, 2019, 9:57. [41] Sousa Neves J, Santos Faria D, Cerqueira M, Afonso MC, Teixeira F. Relevance of ultrasonography in assessing disease activity in patients with idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2018, 21:233-239. [42] Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients[J]. Rheumatol Int, 2009, 29:989-994. [43] Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease[J]. Arthritis Rheum, 2009, 60:2183-2192. [44] Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, Du Bois RM, Hansell DM, Nicholson AG. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis[J]. Histopathology, 2004, 44:585-596. [45] Huang ZG, Gao BX, Chen H, Yang MX, Chen XL, Yan R, Lu X, Shi KN, Chan Q, Wang GC. An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis[J]. PLoS One, 2017, 12:E181069. [46] An P, Zhang CY, Zhang YX, Gao SJ. Application of dual-energy CT in skeletal musculoskeletal system[J]. Lin Chuang Fang She Xue Za Zhi, 2019, 38:1339-1342.[安鹏, 张晨颖, 张银霞, 高思佳. 双能量CT在骨骼肌肉系统病变中的应用[J].临床放射学杂志, 2019, 38:1339-1342.] [47] Huang B, Lü DH, Ke KL, Song XC, Xie QP, Zhao SH. A review of 222 cases of dermatomyositis or polymyositis with malignant tumor[J]. Lin Chuang Hui Cui, 2013, 28:792-794.[黄斌, 吕冬华, 柯孔良, 宋效成, 谢秋平, 赵书红. 皮肌炎或多发性肌炎伴发恶性肿瘤222例国内文献复习[J]. 临床荟萃, 2013, 28:792-794.] [48] Thogersen KF, Simonsen JA, Hvidsten S, Gerke O, Jacobsen S, Høilund-Carlsen PF, Buch-Olsen KM, Diederichsen LP. Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy[J]. EJNMMI Res, 2017, 7:97. [49] Li Y, Zhou Y, Wang Q. Multiple values of 18F-FDG PET/CT in idiopathic inflammatory myopathy[J]. Clin Rheumatol, 2017, 36:2297-2305. [50] Fernández-Rodríguez P, Martín-Marcuartu JJ, Jiménez-Hoyuela JM. Idiopathic inflammatory myopathy and antisynthetase syndrome:early diagnosis by 99mTc-HDP bone scintigraphy[J]. Clin Nucl Med, 2018, 43:939-940. |